The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, an investigational therapeutic from Purdue Pharma L.P., for the treatment of patients with malignant ...
OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it. A judge on Wednesday said he ...
OxyContin maker Purdue Pharma ‘s $7 billion-plus plan to settle thousands of lawsuits over the toll of opioids will be sent to local governments, people who became addicted to the drug and other ...
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it. A judge on Wednesday said he ...
OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it. A judge on Wednesday said he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback